Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atropine 0.05% for Myopia Progression in Children
NCT07164092Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Sponsor
- Mansoura University
- Modality
- Small Molecules
- Drugs
- Myopine
- Conditions
- myopia
01
Overview
Phase 3, randomised, double-blind trial of Myopine in myopia (2 arms), sponsored by Mansoura University. Primary endpoint: Change in ocular axial length at 24 months. Planned start Sep 2025; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Atropine 0.05% Eye
Atropine sulphate 0.05% eye drops nightly.
Placebo Eye
Placebo eye drops nightly.
03
Endpoints
Primary
Change in ocular axial length
Secondary
Change in spherical equivalent refraction
Best-corrected distance visual acuity
Beyond the preview
Go deeper on NCT07164092.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164092.